On March 17, 2023 Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, reported the company will discuss its fourth quarter and full-year 2022 financial results and provide a business update on Friday, March 31, 2023, at 8:00 am Eastern Time (Press release, Chemomab, MAR 17, 2023, View Source [SID1234628984]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
During the event, Chemomab’s management team will review fourth quarter and full-year 2022 performance, discuss recent and upcoming developments and conduct a live question-and-answer session.
A replay of the call will be available on Chemomab’s website for 90 days at www.chemomab.com.
Live Webcast and Conference Call at 8:00 am Eastern Time, Friday, March 31, 2023
Click this Webcast link to access the live webcast or replay.
The live webcast and replay can also be accessed at the News & Events section of the Investors page on the Chemomab website at investors.chemomab.com/events.
Conference Call Access via Telephone
US Investors:
+1 (877) 407-9208
International Investors:
+1 (201) 493-6784
Conference Passcode:
#13735392
Or click on Call me for instant telephone access to the event
Please call 5-10 minutes before the scheduled start time, enter the conference passcode and ask the operator for the Chemomab conference call.